Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-07-12 DOI:10.1080/14737167.2025.2532805

Konstantinos Drakos, Ariston Karagiorgis, Olga Katsarou, Efrosyni Nomikou, Sofia Vakalopoulou, Marina Economou, Helen Pergantou

{"title":"Switching hemophilia A patients to an extended half-life agent on a prophylactic basis: an economic appraisal.","authors":"Konstantinos Drakos, Ariston Karagiorgis, Olga Katsarou, Efrosyni Nomikou, Sofia Vakalopoulou, Marina Economou, Helen Pergantou","doi":"10.1080/14737167.2025.2532805","DOIUrl":null,"url":null,"abstract":"Background: Gaining an understanding of transitioning hemophilia patients to an extended half-life (EHL) agent requires real-world data, encompassing various outcomes, which would help assessing the impact of the switch, for patients and the healthcare system. We investigate the economic implications of switching from standard half-life (SHL) recombinant factor VIII (rFVIII) from either prophylaxis or on-demand, to EHL rFVIII efmoroctocog alfa (FVIIIFc) prophylaxis.Research design and methods: The study involved 48 patients with hemophilia A from the 5 specialized hemophilia centers in Greece. Patients switched from prophylactic or on-demand treatment using a SHL factor VIII to a rFVIIIFc on prophylaxis only. Data was gathered for the 12-month period before and after switch. Using standard t-tests and regression analysis, we compared the direct treatment cost between the pre and post switch time, focusing on regimens' differential costs.Results: There is no statistically significant cost increase compared to the core rFVIII regimen used before the switch, when only patients that were previously on prophylaxis were considered. However, there is a statistically significant reduction in cost across treatment styles.Conclusions: The analysis confirms the advantages offered by prophylaxis with rFVIIIFc from an economic standpoint for the Greek healthcare system, in accordance with other studies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-8"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2532805","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gaining an understanding of transitioning hemophilia patients to an extended half-life (EHL) agent requires real-world data, encompassing various outcomes, which would help assessing the impact of the switch, for patients and the healthcare system. We investigate the economic implications of switching from standard half-life (SHL) recombinant factor VIII (rFVIII) from either prophylaxis or on-demand, to EHL rFVIII efmoroctocog alfa (FVIIIFc) prophylaxis.

Research design and methods: The study involved 48 patients with hemophilia A from the 5 specialized hemophilia centers in Greece. Patients switched from prophylactic or on-demand treatment using a SHL factor VIII to a rFVIIIFc on prophylaxis only. Data was gathered for the 12-month period before and after switch. Using standard t-tests and regression analysis, we compared the direct treatment cost between the pre and post switch time, focusing on regimens' differential costs.

Results: There is no statistically significant cost increase compared to the core rFVIII regimen used before the switch, when only patients that were previously on prophylaxis were considered. However, there is a statistically significant reduction in cost across treatment styles.

Conclusions: The analysis confirms the advantages offered by prophylaxis with rFVIIIFc from an economic standpoint for the Greek healthcare system, in accordance with other studies.

查看原文本刊更多论文

在预防的基础上将血友病患者转换为延长半衰期的药物：经济评估。

背景：了解血友病患者过渡到延长半衰期（EHL）药物需要真实世界的数据，包括各种结果，这将有助于评估转换对患者和医疗保健系统的影响。我们研究了从标准半衰期（SHL）重组因子VIII （rFVIII）从预防或按需转向EHL rFVIII efmoroccog alfa （fviii ifc）预防的经济意义。研究设计和方法：本研究涉及来自希腊5个血友病专科中心的48名A型血友病患者。患者从使用SHL因子VIII的预防性或按需治疗切换到仅用于预防的rfviii ifc。数据收集了转换前后12个月的数据。使用标准t检验和回归分析，我们比较了切换前后时间的直接治疗成本，重点关注方案的差异成本。结果：与转换前使用的核心rFVIII方案相比，仅考虑先前接受预防治疗的患者时，没有统计学上显著的成本增加。然而，在统计上，不同治疗方式的成本显著降低。结论：与其他研究一致，分析证实了从经济角度来看，希腊卫生保健系统采用rfviii ifc预防提供的优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.